LINC01910: A Potential Drug Target and Biomarker (G101060542)

Target Name: LINC01910

NCBI ID: G101060542

LINC01910

Other Name(s): long intergenic non-protein coding RNA 1910 | Long intergenic non-protein coding RNA 1910

LINC01910: A Potential Drug Target and Biomarker

LINC01910 is a protein that is expressed in various tissues of the human body, including the brain, heart, and kidneys. Its full name is long non-coding RNA gene 01910, and it is a known gene that has been associated with various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. In recent years, researchers have been interested in investigating the potential drug targets of LINC01910, as well as its potential as a biomarker for certain diseases.

The LINC01910 gene is a non-coding RNA gene that is located on chromosome 6p21. It is transcribed into a protein that is approximately 21 kilobases (kb) in length. The protein produced by LINC01910 is involved in various cellular processes, including cell adhesion, migration, and survival. It is also involved in the regulation of various signaling pathways, including the TGF-β pathway and the NF-kappa-B pathway.

One of the key functions of LINC01910 is its role in cell adhesion. This protein is known to be involved in the regulation of tight junctions, which are a type of cell-cell adhesion that helps to maintain tissue structure and prevent the loss of liquids in the body. LINC01910 has been shown to play a role in the regulation of tight junctions in various tissues, including the brain and the kidney.

Another function of LINC01910 is its role in cell migration. This protein is involved in the regulation of cell migration, which is the movement of cells from one location to another in the body. LINC01910 has been shown to play a role in the regulation of cell migration in various tissues, including the brain and the pancreas.

In addition to its functions in cell adhesion and migration, LINC01910 is also involved in the regulation of various signaling pathways. This protein is known to be involved in the regulation of the TGF-β pathway, which is a key pathway involved in cell growth, differentiation, and survival. LINC01910 has also been shown to play a role in the regulation of the NF-kappa-B pathway, which is involved in inflammation and stress responses.

The potential drug targets of LINC01910 are vast, as this protein is involved in various cellular processes that are important for the health and function of the body. As such, LINC01910 is a promising drug target for a variety of diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.

One of the key advantages of LINC01910 as a drug target is its relatively simple structure. This protein is only approximately 21 kb in length, which makes it relatively easy to identify and target. Additionally, LINC01910 has been shown to have a relatively stable expression level in various tissues, which makes it a relatively stable drug target.

Another advantage of LINC01910 as a drug target is its involvement in various signaling pathways. This protein is involved in the regulation of multiple signaling pathways, including the TGF-β pathway and the NF-kappa-B pathway. As such, LINC01910 has been shown to play a role in the regulation of various cellular processes that are important for the health and function of the body. This makes it a potential drug target for a variety of diseases.

In addition to its potential as a drug target, LINC01910 has also been shown to be a potential biomarker for several diseases. This protein is involved in the regulation of various signaling pathways, which makes it a potential biomarker for a variety of diseases. For example, LINC01910 has been shown to be involved in the regulation of the TGF-β pathway, which is associated with a number of diseases, including cancer. Additionally, LINC01910 has

Protein Name: Long Intergenic Non-protein Coding RNA 1910

The "LINC01910 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about LINC01910 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets